Chugai and its Businesses

The company was first established as Chugai Shinyaku Co., Ltd. in March 1925. 18 years later, in March 1943, the company was reorganized as a corporation based in Tokyo and assumed its present name as Chugai Pharmaceutical Co., Ltd.
Chugai has established its mission statement and Chugai Group Code of Conduct (CCC) as a business standard. In addition, we have formulated “TOP I 2030,” the growth strategy to become a Top Innovator in 2030.
Click below to view Mission Statement, Chugai Group Code of Conduct (CCC) or Growth Strategy in more detail.
Chugai’s performance is subject to major impact from a range of factors. Principal risk factors are related to new product development, market environment changes, side effects, changes within the medical/insurance system, intellectual property rights, our strategic alliance with Roche, and foreign exchange rate fluctuations. There are other risk factors as well. The Company will make every effort to prevent, minimize and respond appropriately to the risks it faces.
To learn more about the risks Chugai prepares for, click the link below.

Business Risks

Chugai is an R&D focused pharmaceutical company specializing in prescription drugs, especially biopharmaceuticals. Since entering into a strategic alliance with Roche in October 2002, Chugai has aggressively conducted R&D activities for prescription drugs as a key member of the Roche Group, both in Japan and overseas. In addition to our pioneering advances in antibody engineering technologies, we have industry-leading research and technology capabilities, backed by technologies for small and mid-size molecules, access to the Roche Group’s world-class research infrastructure and a strong external network with academia and other research institutions.
For further details regarding our business and products, click the links below.

A more detailed overview of Chugai’s businesses is provided in the annual report.

Annual Reports

At Chugai, we first develop proprietary technologies that are applicable to drug discovery, and then apply them to drugs that target disease-causing molecules. With this approach, we aim to create first-in-class, best-in-class new drugs that can be differentiated from the drugs of other companies. Our research organization aims not just to achieve quantitative productivity—the discovery of a certain number of new compounds in a given period—but also to enhance our ability to create innovative medicines over time. To do this, we must increasingly be aware of -and where possible anticipate—developments that may affect the healthcare environment in which new medicines will be used. Accordingly, it is important to consider how existing therapies, the pharmaceutical market environment, the economics of healthcare, and other factors may evolve in the next 10 years. Our overriding goal is to continue developing innovative new therapies that address unmet medical needs and enhance patient well-being and quality of life.

To view our latest development pipeline, click the link below. Development status is updated quarterly in conjunction with financial reporting.

Development Pipeline

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.
Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in-vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.
The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2017 employed about 94,000 people worldwide. In 2017, Roche invested CHF 10.4 billion in R&D and posted sales of CHF 53.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.

For more information, please visit the Roche website www.roche.com.

Chugai is committed to continuously increase corporate value and respond appropriately and fairly to the requests of shareholders and other stakeholders. To fulfill this commitment, we have positioned the enhancement of corporate governance as an important management task and are building a system that emphasizes prompt decision-making, clarification of executive responsibilities, and management transparency.
Based on these concepts, Chugai has taken measures to strengthen functions of the Board of Directors and speed up its decision-making, such as optimizing the number of directors, nominating outside directors to check management from the stakeholder viewpoint, and introducing an executive officer system that aims at clarifying executive responsibilities. Furthermore, aiming at accurately responding to changes in global business environment as well as ensuring business deployment with a proper corporate attitude, the Chugai International Council (CIC) has been formed with specialists from various fields inside and outside Japan to provide advice for the management. Going forward, the Company will further pursue sound management and promote swifter decision-making, clarification of executive responsibility and enhancement of management transparency.
For more details, please visit the following site.

Corporate Governance


Chugai’s mission centers on Sustainability. We are dedicated to the creation of innovative medical products and services for the benefit of the medical community and human health around the world. We are committed to creating innovative pharmaceuticals by strategically allocating resources in the pursuit of innovation. In particular, we are focusing on unmet medical needs, where treatments remain insufficient, despite the pronounced needs of patients and medical professionals. Contributing to the health of people all over the world is the Group’s ultimate social responsibility.

Moreover, the Group seeks to contribute to sustainable growth. To do so, Chugai is actively involved—globally and locally—in aggressively promoting measures to preserve the environment, such as those aimed at reducing global CO2 emissions.

More information on Chugai’s performance can be found at the following link.

Basic Policy (Creation of Shared Value)

Both our Mission Statement and Business Conduct Guidelines directly address protecting the global environment, and prevention of global warming is one of the most important aspect for environmental preservation.

The Chugai Group is taking concrete steps to prevent global warming. These include utilizing environment-friendly facilities, maximizing energy efficiency, adopting solar power, introducing hybrid vehicles throughout the fleet and purchasing Green Power Certificates.

More information on Chugai’s effort to reduce CO2 emissions can be found at the following link.

Climate Change Countermeasures

In the development of medicines, we must conduct clinical trials to ensure that our drugs are both safe and effective. However, before medicine can be tested in humans, in compliance with worldwide regulations, we must first obtain efficacy and safety data from studies involving animals. It is not yet technologically possible to accurately recreate complicated physiological phenomenon outside of a living body, therefore testing in animals remains necessary to provide new safe and effective medicines to the world.

Chugai complies with domestic regulations and guidelines regarding the care and use of animals, and has established the Institutional Animal Care and Use Committee (IACUC) to confirm, evaluate, and monitor compliance with the 3R principles, to review and approve experimental protocols, and to provide education and training for personnel engaged in the care and use of animals.

Our activities have been evaluated by AAALAC International, the independent and globally-recognized evaluation organization with which Chugai has maintained full accreditation since 2007, and will continues to be it.

Policy for Research by Animals

As a member of society, Chugai engages in social contribution activities to help solve social issues, contributing our resources and professional capabilities without seeking direct compensation. We will conduct social contribution activities while leveraging our capabilities (strengths, technologies, expertise) in promoting businesses involved in healthcare and well-being. Specifically, we have prioritized the five fields of “Healthcare,” “Social Welfare,” “Inclusive Society,” “Next Generation Development,” and “Local Communities,” and will continue to meet social needs.
More information on Chugai’s effort to contribute to society can be found at the following link.

Financial Performance and Reporting

The company reports on a calendar-year basis with a fiscal year-end of December 31.
Quarterly results are available from the link below. The Events & Presentations website provides the schedule of results announcements.
Financial statements (income, balance sheet and cash flows), product sales, and key financial indicators for the past five years are available on the website. Other financial materials are also available for download.
These appear in the quarterly financial statements. In the event that performance is expected to differ materially from the forecast, Chugai may issue a press release, which can be viewed from the news section. Chugai can also notify you of releases via E-mail Alerts and RSS feeds. Click here for convenient registration.
Research and development expenses for the past five years are available in the Income Statement section. Please click here to view them.

Financial Results and Other Indicators

The presentation materials and webcast are provided on the website. Click here to view them.

Presentation Materials

Various IR materials are posted on the website. Please click here to view them.

Reports & Downloads

Please check the Events & Presentations section for IR schedules.

Events & Presentations

The E-mail Alert service delivers the latest IR updates. We also provide RSS feeds.
You may contact us by phone, fax or online inquiries form. Please click here for details.

Chugai Shares

Chugai’s stock is listed on the first section of the Tokyo Stock Exchange under the code 4519.
Chugai’s stock was first listed on the Tokyo Stock Exchange in March 1956.
Shareholders of record on June 30 and December 31 will be eligible for interim and year-end dividends, respectively. Interim dividends are typically paid in early September, and year-end dividends are usually paid following the Annual General Meeting of shareholders in March.
The Annual General Meeting of Shareholders is held in March, following the close of the fiscal year in December.
If you are unable to attend the meeting, you can exercise your voting rights in writing or via electromagnetic method (the Internet, etc.).
  • Like
  • Post
  • LINE it!
  • E-mail
Back to top